DK3034079T3 - PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS - Google Patents

Info

Publication number

DK3034079T3

DK3034079T3 DK15187794.1T DK15187794T DK3034079T3 DK 3034079 T3 DK3034079 T3 DK 3034079T3 DK 15187794 T DK15187794 T DK 15187794T DK 3034079 T3 DK3034079 T3 DK 3034079T3

Authority

DK

Denmark

Prior art keywords

substituted

independently selected

aliphatic

compound

cognitive impairment

Prior art date

2010-11-15

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 85
• 239000000203 mixture Substances 0.000 title abstract description 71
• 230000001149 cognitive effect Effects 0.000 title description 23
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical class C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
• 208000010877 cognitive disease Diseases 0.000 claims abstract description 153
• 208000028698 Cognitive impairment Diseases 0.000 claims abstract description 109
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 41
• 208000027061 mild cognitive impairment Diseases 0.000 claims abstract description 40
• 208000028173 post-traumatic stress disease Diseases 0.000 claims abstract description 38
• 206010012289 Dementia Diseases 0.000 claims abstract description 37
• 201000000980 schizophrenia Diseases 0.000 claims abstract description 34
• 210000003169 central nervous system Anatomy 0.000 claims abstract description 14
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
• 150000001875 compounds Chemical class 0.000 claims description 277
• -1 -R3 Chemical group 0.000 claims description 86
• 125000001424 substituent group Chemical group 0.000 claims description 65
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
• 238000011282 treatment Methods 0.000 claims description 42
• 150000003839 salts Chemical class 0.000 claims description 40
• 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 39
• 125000001072 heteroaryl group Chemical group 0.000 claims description 39
• 125000003118 aryl group Chemical group 0.000 claims description 36
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
• 101100295738 Gallus gallus COR3 gene Proteins 0.000 claims description 30
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 29
• 125000005842 heteroatom Chemical group 0.000 claims description 28
• 125000001931 aliphatic group Chemical group 0.000 claims description 27
• 229910052736 halogen Inorganic materials 0.000 claims description 25
• 150000002367 halogens Chemical class 0.000 claims description 25
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 24
• 208000015114 central nervous system disease Diseases 0.000 claims description 22
• 125000004429 atom Chemical group 0.000 claims description 21
• 229910052757 nitrogen Inorganic materials 0.000 claims description 21
• 125000006574 non-aromatic ring group Chemical group 0.000 claims description 21
• 229910052760 oxygen Inorganic materials 0.000 claims description 21
• 239000008194 pharmaceutical composition Substances 0.000 claims description 19
• 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 claims description 17
• 229910052739 hydrogen Inorganic materials 0.000 claims description 17
• 239000001257 hydrogen Substances 0.000 claims description 17
• 229910052717 sulfur Inorganic materials 0.000 claims description 17
• 230000007000 age related cognitive decline Effects 0.000 claims description 14
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 12
• 125000004076 pyridyl group Chemical group 0.000 claims description 11
• 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 10
• MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 claims description 10
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
• 125000004043 oxo group Chemical group O=* 0.000 claims description 10
• 125000000464 thioxo group Chemical group S=* 0.000 claims description 10
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 10
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
• 206010027175 memory impairment Diseases 0.000 claims description 7
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
• 201000011240 Frontotemporal dementia Diseases 0.000 claims description 5
• 201000002832 Lewy body dementia Diseases 0.000 claims description 5
• 201000004810 Vascular dementia Diseases 0.000 claims description 5
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
• 239000002671 adjuvant Substances 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 229910052731 fluorine Inorganic materials 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 3
• 201000011510 cancer Diseases 0.000 claims description 3
• 208000009829 Lewy Body Disease Diseases 0.000 claims 1
• 239000000556 agonist Substances 0.000 abstract description 46
• 238000011275 oncology therapy Methods 0.000 abstract description 28
• 102000027484 GABAA receptors Human genes 0.000 abstract description 24
• 108091008681 GABAA receptors Proteins 0.000 abstract description 24
• 150000004892 pyridazines Chemical class 0.000 abstract description 4
• 241000700159 Rattus Species 0.000 description 97
• 238000012360 testing method Methods 0.000 description 71
• 230000000694 effects Effects 0.000 description 50
• 102000005962 receptors Human genes 0.000 description 48
• 108020003175 receptors Proteins 0.000 description 48
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 43
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 42
• 239000000243 solution Substances 0.000 description 42
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 41
• HICZHPFZMDTJBP-UHFFFAOYSA-N methyl 3,5-diphenylpyridazine-4-carboxylate Chemical compound COC(=O)C1=C(C=2C=CC=CC=2)C=NN=C1C1=CC=CC=C1 HICZHPFZMDTJBP-UHFFFAOYSA-N 0.000 description 41
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
• 229910001868 water Inorganic materials 0.000 description 37
• 230000002829 reductive effect Effects 0.000 description 36
• 238000010171 animal model Methods 0.000 description 35
• 235000002639 sodium chloride Nutrition 0.000 description 35
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
• 239000003795 chemical substances by application Substances 0.000 description 30
• 239000011541 reaction mixture Substances 0.000 description 30
• 238000012549 training Methods 0.000 description 29
• 239000003981 vehicle Substances 0.000 description 29
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
• 230000003920 cognitive function Effects 0.000 description 27
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 26
• 210000000287 oocyte Anatomy 0.000 description 26
• 210000001320 hippocampus Anatomy 0.000 description 25
• 239000007787 solid Substances 0.000 description 25
• 238000004809 thin layer chromatography Methods 0.000 description 25
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• 239000003814 drug Substances 0.000 description 23
• 238000012800 visualization Methods 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 22
• 239000012043 crude product Substances 0.000 description 20
• 230000015654 memory Effects 0.000 description 20
• 208000024891 symptom Diseases 0.000 description 20
• 241000282412 Homo Species 0.000 description 19
• 230000001771 impaired effect Effects 0.000 description 19
• 229940079593 drug Drugs 0.000 description 16
• 230000014759 maintenance of location Effects 0.000 description 16
• CAJUSRIHDIZNNF-UHFFFAOYSA-N 3-(3-hydroxypropylsulfanyl)-6,6-dimethyl-1-(1,3-thiazol-2-yl)-5,7-dihydro-2-benzothiophen-4-one Chemical compound S1C(SCCCO)=C2C(=O)CC(C)(C)CC2=C1C1=NC=CS1 CAJUSRIHDIZNNF-UHFFFAOYSA-N 0.000 description 15
• 229960003529 diazepam Drugs 0.000 description 15
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 15
• 235000019439 ethyl acetate Nutrition 0.000 description 15
• 210000004556 brain Anatomy 0.000 description 14
• 239000012267 brine Substances 0.000 description 14
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
• 239000002904 solvent Substances 0.000 description 14
• 239000007858 starting material Substances 0.000 description 14
• 238000005160 1H NMR spectroscopy Methods 0.000 description 13
• 238000012347 Morris Water Maze Methods 0.000 description 13
• 235000013305 food Nutrition 0.000 description 13
• 238000004949 mass spectrometry Methods 0.000 description 13
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 12
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
• 210000001638 cerebellum Anatomy 0.000 description 12
• 238000004440 column chromatography Methods 0.000 description 12
• 230000013016 learning Effects 0.000 description 12
• 230000006886 spatial memory Effects 0.000 description 12
• 238000003786 synthesis reaction Methods 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 241000269370 Xenopus <genus> Species 0.000 description 11
• 230000003542 behavioural effect Effects 0.000 description 11
• 210000004027 cell Anatomy 0.000 description 11
• 230000006735 deficit Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 239000000741 silica gel Substances 0.000 description 11
• 229910002027 silica gel Inorganic materials 0.000 description 11
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
• 230000000971 hippocampal effect Effects 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 239000000523 sample Substances 0.000 description 10
• DUFCOYKJGMEMLU-UHFFFAOYSA-N 6-methyl-3,5-diphenylpyridazine-4-carboxylic acid Chemical compound OC(=O)C1=C(C=2C=CC=CC=2)C(C)=NN=C1C1=CC=CC=C1 DUFCOYKJGMEMLU-UHFFFAOYSA-N 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 230000003281 allosteric effect Effects 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• 238000013265 extended release Methods 0.000 description 9
• 125000002950 monocyclic group Chemical group 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 230000001225 therapeutic effect Effects 0.000 description 9
• 239000002585 base Substances 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 8
• 229960004381 flumazenil Drugs 0.000 description 8
• 235000019253 formic acid Nutrition 0.000 description 8
• 238000004128 high performance liquid chromatography Methods 0.000 description 8
• 230000001965 increasing effect Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 230000004044 response Effects 0.000 description 8
• 239000012453 solvate Substances 0.000 description 8
• YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000000460 chlorine Substances 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 230000001419 dependent effect Effects 0.000 description 7
• 231100000673 dose–response relationship Toxicity 0.000 description 7
• 239000003480 eluent Substances 0.000 description 7
• 239000000543 intermediate Substances 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
• 238000011670 long-evans rat Methods 0.000 description 7
• 239000000018 receptor agonist Substances 0.000 description 7
• 229940044601 receptor agonist Drugs 0.000 description 7
• ZTULFWLVIJLMOV-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-ethenyl-1,3-oxazole Chemical compound C=CC1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 ZTULFWLVIJLMOV-UHFFFAOYSA-N 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 230000002411 adverse Effects 0.000 description 6
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
• 125000002619 bicyclic group Chemical group 0.000 description 6
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
• 238000012512 characterization method Methods 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 230000008020 evaporation Effects 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• 238000009472 formulation Methods 0.000 description 6
• 125000000623 heterocyclic group Chemical group 0.000 description 6
• 230000001537 neural effect Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 239000000700 radioactive tracer Substances 0.000 description 6
• WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 5
• 230000032683 aging Effects 0.000 description 5
• 230000006399 behavior Effects 0.000 description 5
• KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 5
• 230000003750 conditioning effect Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 239000012467 final product Substances 0.000 description 5
• JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
• 229940002612 prodrug Drugs 0.000 description 5
• 239000000651 prodrug Substances 0.000 description 5
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• JCLXVCCOPHDTHD-UHFFFAOYSA-N 1-[2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazol-4-yl]ethanol Chemical compound CC(O)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 JCLXVCCOPHDTHD-UHFFFAOYSA-N 0.000 description 4
• SZNJAJJXVLFODY-UHFFFAOYSA-N 1-[2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazol-4-yl]ethanone Chemical compound CC(=O)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 SZNJAJJXVLFODY-UHFFFAOYSA-N 0.000 description 4
• YSCWREAJOKCWDS-UHFFFAOYSA-N 2-[2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazol-4-yl]propan-2-ol Chemical compound CC(C)(O)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 YSCWREAJOKCWDS-UHFFFAOYSA-N 0.000 description 4
• GKGOBNAAIVSZOW-UHFFFAOYSA-N 6-oxo-4-phenyl-1h-pyridazine-5-carboxylic acid Chemical compound C1=NNC(=O)C(C(=O)O)=C1C1=CC=CC=C1 GKGOBNAAIVSZOW-UHFFFAOYSA-N 0.000 description 4
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 4
• 206010052804 Drug tolerance Diseases 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 230000003935 attention Effects 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 230000019771 cognition Effects 0.000 description 4
• 230000003931 cognitive performance Effects 0.000 description 4
• 229940125904 compound 1 Drugs 0.000 description 4
• 229940125810 compound 20 Drugs 0.000 description 4
• 229940126086 compound 21 Drugs 0.000 description 4
• 229940126208 compound 22 Drugs 0.000 description 4
• 229940125833 compound 23 Drugs 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• 230000001054 cortical effect Effects 0.000 description 4
• 125000000392 cycloalkenyl group Chemical group 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 230000026781 habituation Effects 0.000 description 4
• 208000014674 injury Diseases 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 230000007787 long-term memory Effects 0.000 description 4
• 230000008897 memory decline Effects 0.000 description 4
• JUEBWVAGNOLFFE-UHFFFAOYSA-N methyl 2-[(3,5-diphenylpyridazine-4-carbonyl)amino]-3-hydroxypropanoate Chemical compound COC(=O)C(CO)NC(=O)C1=C(C=2C=CC=CC=2)C=NN=C1C1=CC=CC=C1 JUEBWVAGNOLFFE-UHFFFAOYSA-N 0.000 description 4
• 125000004430 oxygen atom Chemical group O* 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 230000005855 radiation Effects 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
• QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
• VXGMUWOLLNOZGP-UHFFFAOYSA-N 4-(bromomethyl)-2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazole Chemical compound BrCC1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 VXGMUWOLLNOZGP-UHFFFAOYSA-N 0.000 description 3
• 125000006163 5-membered heteroaryl group Chemical group 0.000 description 3
• RLJLXKXLYCEMMA-UHFFFAOYSA-N 6-oxo-4-phenyl-1h-pyridazine-5-carbonitrile Chemical compound O=C1NN=CC(C=2C=CC=CC=2)=C1C#N RLJLXKXLYCEMMA-UHFFFAOYSA-N 0.000 description 3
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
• 229920000858 Cyclodextrin Polymers 0.000 description 3
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
• 240000007472 Leucaena leucocephala Species 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• BOFTZLDGPOOFSB-UHFFFAOYSA-N [2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazol-4-yl]methanol Chemical compound OCC1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 BOFTZLDGPOOFSB-UHFFFAOYSA-N 0.000 description 3
• 238000010521 absorption reaction Methods 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 230000004888 barrier function Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 229910052796 boron Inorganic materials 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 230000007278 cognition impairment Effects 0.000 description 3
• 229940125846 compound 25 Drugs 0.000 description 3
• 125000000753 cycloalkyl group Chemical group 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 238000000185 intracerebroventricular administration Methods 0.000 description 3
• 230000008449 language Effects 0.000 description 3
• 230000006742 locomotor activity Effects 0.000 description 3
• 230000007334 memory performance Effects 0.000 description 3
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
• SSUWNMUERTVJBS-UHFFFAOYSA-N methyl 3-chloro-5-phenylpyridazine-4-carboxylate Chemical compound COC(=O)C1=C(Cl)N=NC=C1C1=CC=CC=C1 SSUWNMUERTVJBS-UHFFFAOYSA-N 0.000 description 3
• 230000000897 modulatory effect Effects 0.000 description 3
• QFNPIUWGBXCEGZ-UHFFFAOYSA-N n-(1-hydroxypropan-2-yl)-3,5-diphenylpyridazine-4-carboxamide Chemical compound OCC(C)NC(=O)C1=C(C=2C=CC=CC=2)C=NN=C1C1=CC=CC=C1 QFNPIUWGBXCEGZ-UHFFFAOYSA-N 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 238000002600 positron emission tomography Methods 0.000 description 3
• 235000015320 potassium carbonate Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000002603 single-photon emission computed tomography Methods 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000008223 sterile water Substances 0.000 description 3
• 239000000375 suspending agent Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
• 239000003039 volatile agent Substances 0.000 description 3
• 239000000080 wetting agent Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
• ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 2
• TYHNOWKURZGXNY-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-ethyl-1,3-oxazole Chemical compound CCC1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 TYHNOWKURZGXNY-UHFFFAOYSA-N 0.000 description 2
• APCDBOULVOBSAG-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-methyl-1,3-oxazole Chemical compound CC1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 APCDBOULVOBSAG-UHFFFAOYSA-N 0.000 description 2
• BFGFRUXJMFGDTK-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-propan-2-yl-1,3-oxazole Chemical compound CC(C)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 BFGFRUXJMFGDTK-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 241000416162 Astragalus gummifer Species 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
• 206010010904 Convulsion Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• 239000001116 FEMA 4028 Substances 0.000 description 2
• 241000206672 Gelidium Species 0.000 description 2
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
• 229930182566 Gentamicin Natural products 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 239000007821 HATU Substances 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 206010039897 Sedation Diseases 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229920001615 Tragacanth Polymers 0.000 description 2
• 241000269368 Xenopus laevis Species 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000000217 alkyl group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 230000003444 anaesthetic effect Effects 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000012300 argon atmosphere Substances 0.000 description 2
• 230000001174 ascending effect Effects 0.000 description 2
• 125000003725 azepanyl group Chemical group 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000000440 bentonite Substances 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• 229910000278 bentonite Inorganic materials 0.000 description 2
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
• 229960004853 betadex Drugs 0.000 description 2
• 230000008499 blood brain barrier function Effects 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 210000001218 blood-brain barrier Anatomy 0.000 description 2
• 150000001649 bromium compounds Chemical class 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000037411 cognitive enhancing Effects 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 230000036461 convulsion Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 201000010099 disease Diseases 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 210000005153 frontal cortex Anatomy 0.000 description 2
• 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 230000010365 information processing Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 150000004694 iodide salts Chemical class 0.000 description 2
• YKYOQIXTECBVBB-AWEZNQCLSA-N l-655,708 Chemical compound O=C1C2=CC(OC)=CC=C2N2C=NC(C(=O)OCC)=C2[C@@H]2CCCN21 YKYOQIXTECBVBB-AWEZNQCLSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000000787 lecithin Substances 0.000 description 2
• 235000010445 lecithin Nutrition 0.000 description 2
• 229940067606 lecithin Drugs 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• KYSVISXALMGSOQ-UHFFFAOYSA-N methyl 2-(3,5-diphenylpyridazin-4-yl)-4,5-dihydro-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 KYSVISXALMGSOQ-UHFFFAOYSA-N 0.000 description 2
• GADIKQPUNWAMEB-UHFFFAOYSA-N methyl 4-ethyl-6,7-dimethoxy-9H-pyrido[5,4-b]indole-3-carboxylate Chemical compound N1C2=CC(OC)=C(OC)C=C2C2=C1C=NC(C(=O)OC)=C2CC GADIKQPUNWAMEB-UHFFFAOYSA-N 0.000 description 2
• CPRWGUJDKSFUJQ-UHFFFAOYSA-N n-methyl-3,5-diphenylpyridazine-4-carboxamide Chemical compound CNC(=O)C1=C(C=2C=CC=CC=2)C=NN=C1C1=CC=CC=C1 CPRWGUJDKSFUJQ-UHFFFAOYSA-N 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 230000009437 off-target effect Effects 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 239000012044 organic layer Substances 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• 238000007427 paired t-test Methods 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 230000006977 prepulse inhibition Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000036280 sedation Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
• 230000003997 social interaction Effects 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 235000010199 sorbic acid Nutrition 0.000 description 2
• 239000004334 sorbic acid Substances 0.000 description 2
• 229940075582 sorbic acid Drugs 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000009182 swimming Effects 0.000 description 2
• 210000000225 synapse Anatomy 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 235000010487 tragacanth Nutrition 0.000 description 2
• 239000000196 tragacanth Substances 0.000 description 2
• 229940116362 tragacanth Drugs 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 229910052727 yttrium Inorganic materials 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 102100027831 14-3-3 protein theta Human genes 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• RFMJODGJFJZPKV-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-methyl-2,3-dihydro-1,3-oxazole Chemical compound N1C(C)=COC1C1=C(C=2C=CC=CC=2)C=NN=C1C1=CC=CC=C1 RFMJODGJFJZPKV-UHFFFAOYSA-N 0.000 description 1
• CSIMNUWPJIGYLG-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-methyl-4,5-dihydro-1,3-oxazole Chemical compound CC1COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 CSIMNUWPJIGYLG-UHFFFAOYSA-N 0.000 description 1
• RPKWQPPYQGTOJO-UHFFFAOYSA-N 2-(3,5-diphenylpyridazin-4-yl)-4-prop-1-en-2-yl-1,3-oxazole Chemical compound CC(=C)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 RPKWQPPYQGTOJO-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
• TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
• BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
• HPHBOJANXDKUQD-UHFFFAOYSA-N 2-cyanoacetohydrazide Chemical compound NNC(=O)CC#N HPHBOJANXDKUQD-UHFFFAOYSA-N 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• FSUYMKXZLQOFQY-UHFFFAOYSA-N 3,4-dihydro-1,2-benzodithiine Chemical compound C1=CC=C2SSCCC2=C1 FSUYMKXZLQOFQY-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• VYPDRJDYVPYUJY-UHFFFAOYSA-N 4-phenylpyridazine Chemical class C1=CC=CC=C1C1=CC=NN=C1 VYPDRJDYVPYUJY-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 208000031091 Amnestic disease Diseases 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 208000007415 Anhedonia Diseases 0.000 description 1
• 241000269350 Anura Species 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 235000003276 Apios tuberosa Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 206010016754 Flashback Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 101150014889 Gad1 gene Proteins 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 206010021118 Hypotonia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• YKYOQIXTECBVBB-UHFFFAOYSA-N LSM-1859 Chemical compound O=C1C2=CC(OC)=CC=C2N2C=NC(C(=O)OCC)=C2C2CCCN21 YKYOQIXTECBVBB-UHFFFAOYSA-N 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 229910020667 PBr3 Inorganic materials 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102000001675 Parvalbumin Human genes 0.000 description 1
• 108060005874 Parvalbumin Proteins 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
• LUNHCIBEAIKLQJ-UHFFFAOYSA-N [1,2]oxazolo[4,3-c]pyridazine Chemical class C1=CN=NC2=CON=C21 LUNHCIBEAIKLQJ-UHFFFAOYSA-N 0.000 description 1
• SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 150000004703 alkoxides Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 102000003802 alpha-Synuclein Human genes 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000006986 amnesia Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000002426 anti-panic effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000000164 antipsychotic agent Substances 0.000 description 1
• 229940005529 antipsychotics Drugs 0.000 description 1
• 239000002249 anxiolytic agent Substances 0.000 description 1
• 230000000949 anxiolytic effect Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 230000037007 arousal Effects 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000006736 behavioral deficit Effects 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 125000002527 bicyclic carbocyclic group Chemical group 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000003925 brain function Effects 0.000 description 1
• 210000005013 brain tissue Anatomy 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• XNNQFQFUQLJSQT-UHFFFAOYSA-N bromo(trichloro)methane Chemical compound ClC(Cl)(Cl)Br XNNQFQFUQLJSQT-UHFFFAOYSA-N 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Inorganic materials [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 239000002475 cognitive enhancer Substances 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 229940125961 compound 24 Drugs 0.000 description 1
• 229940125851 compound 27 Drugs 0.000 description 1
• 229940127204 compound 29 Drugs 0.000 description 1
• 229940127573 compound 38 Drugs 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 150000008050 dialkyl sulfates Chemical class 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 235000019621 digestibility Nutrition 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 238000003182 dose-response assay Methods 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 230000000857 drug effect Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000003372 electrophysiological method Methods 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 230000003371 gabaergic effect Effects 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000012252 genetic analysis Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 230000007387 gliosis Effects 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 150000004820 halides Chemical class 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 150000002484 inorganic compounds Chemical class 0.000 description 1
• 229910010272 inorganic material Inorganic materials 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 210000001153 interneuron Anatomy 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 229940125425 inverse agonist Drugs 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 210000003140 lateral ventricle Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 244000144972 livestock Species 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 238000013289 male long evans rat Methods 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000007087 memory ability Effects 0.000 description 1
• 230000010387 memory retrieval Effects 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000003924 mental process Effects 0.000 description 1
• 230000006996 mental state Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• SFBVTFYOMRXFEK-UHFFFAOYSA-N methyl 2-(3,5-diphenylpyridazin-4-yl)-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 SFBVTFYOMRXFEK-UHFFFAOYSA-N 0.000 description 1
• YGXFBIMKRQVUKZ-UHFFFAOYSA-N methyl 2-[3-(3-methoxyphenyl)-5-phenylpyridazin-4-yl]-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1=COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=C(OC)C=CC=2)=N1 YGXFBIMKRQVUKZ-UHFFFAOYSA-N 0.000 description 1
• XRPDOSYRLIMDPB-UHFFFAOYSA-N methyl 2-[3-(3-methoxyphenyl)-5-phenylpyridazin-4-yl]-4,5-dihydro-1,3-oxazole-4-carboxylate Chemical compound COC(=O)C1COC(C=2C(=NN=CC=2C=2C=CC=CC=2)C=2C=C(OC)C=CC=2)=N1 XRPDOSYRLIMDPB-UHFFFAOYSA-N 0.000 description 1
• ANSUDRATXSJBLY-UHFFFAOYSA-N methyl 2-amino-3-hydroxypropanoate Chemical compound COC(=O)C(N)CO ANSUDRATXSJBLY-UHFFFAOYSA-N 0.000 description 1
• SNWRCVRZADMSNZ-UHFFFAOYSA-N methyl 6-oxo-4-phenyl-1h-pyridazine-5-carboxylate Chemical compound C1=NNC(=O)C(C(=O)OC)=C1C1=CC=CC=C1 SNWRCVRZADMSNZ-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 230000008450 motivation Effects 0.000 description 1
• 230000036640 muscle relaxation Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• QXJIABOUHLYVHP-UHFFFAOYSA-N n-chloromethanamine Chemical compound CNCl QXJIABOUHLYVHP-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229940126662 negative allosteric modulator Drugs 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 238000010855 neuropsychological testing Methods 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 235000010603 pastilles Nutrition 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229940126027 positive allosteric modulator Drugs 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 235000011181 potassium carbonates Nutrition 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 210000002442 prefrontal cortex Anatomy 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000003236 psychic effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 239000000837 restrainer Substances 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000000698 schizophrenic effect Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000006403 short-term memory Effects 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 230000024188 startle response Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 239000010414 supernatant solution Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1